AU2004209428A1 - Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors - Google Patents

Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors Download PDF

Info

Publication number: AU2004209428A1
Authority: AU; Australia
Prior art keywords: telomerase; suramin; cancer; tumor; patient
Prior art date: 2003-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2004209428A

Other languages

English (en)

Inventor

Jessie L.-S. Au

Guillaume M. Wientjes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-31

Filing date

2004-01-30

Publication date

2004-08-19

2004-01-30 Application filed by Individual filed Critical Individual

2004-08-19 Publication of AU2004209428A1 publication Critical patent/AU2004209428A1/en

Status Abandoned legal-status Critical Current

Links

FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 title claims description 253
229960005314 suramin Drugs 0.000 title claims description 252
108010017842 Telomerase Proteins 0.000 title claims description 230
238000000034 method Methods 0.000 title claims description 132
239000003277 telomerase inhibitor Substances 0.000 title claims description 130
229940043138 pentosan polysulfate Drugs 0.000 title claims description 93
230000000692 anti-sense effect Effects 0.000 title claims description 46
239000000203 mixture Substances 0.000 title claims description 22
206010028980 Neoplasm Diseases 0.000 claims description 357
238000011282 treatment Methods 0.000 claims description 173
210000004027 cell Anatomy 0.000 claims description 170
201000011510 cancer Diseases 0.000 claims description 166
230000000694 effects Effects 0.000 claims description 123
229940123582 Telomerase inhibitor Drugs 0.000 claims description 101
239000003795 chemical substances by application Substances 0.000 claims description 82
230000002401 inhibitory effect Effects 0.000 claims description 82
108091035539 telomere Proteins 0.000 claims description 65
230000002435 cytoreductive effect Effects 0.000 claims description 49
210000004881 tumor cell Anatomy 0.000 claims description 43
230000036470 plasma concentration Effects 0.000 claims description 38
210000001519 tissue Anatomy 0.000 claims description 31
230000001472 cytotoxic effect Effects 0.000 claims description 28
238000002512 chemotherapy Methods 0.000 claims description 27
231100000433 cytotoxic Toxicity 0.000 claims description 27
241000124008 Mammalia Species 0.000 claims description 23
230000012010 growth Effects 0.000 claims description 21
210000000056 organ Anatomy 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 19
230000001225 therapeutic effect Effects 0.000 claims description 18
239000003112 inhibitor Substances 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
201000010099 disease Diseases 0.000 claims description 13
239000012634 fragment Substances 0.000 claims description 13
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
206010060862 Prostate cancer Diseases 0.000 claims description 12
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
239000003937 drug carrier Substances 0.000 claims description 11
238000012423 maintenance Methods 0.000 claims description 11
230000004663 cell proliferation Effects 0.000 claims description 10
239000011859 microparticle Substances 0.000 claims description 10
206010006187 Breast cancer Diseases 0.000 claims description 9
238000011161 development Methods 0.000 claims description 9
238000009472 formulation Methods 0.000 claims description 9
208000026310 Breast neoplasm Diseases 0.000 claims description 8
230000001594 aberrant effect Effects 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
230000002708 enhancing effect Effects 0.000 claims description 8
208000032839 leukemia Diseases 0.000 claims description 8
206010025323 Lymphomas Diseases 0.000 claims description 7
238000004458 analytical method Methods 0.000 claims description 7
230000001419 dependent effect Effects 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 7
238000001890 transfection Methods 0.000 claims description 6
201000009030 Carcinoma Diseases 0.000 claims description 5
206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
238000001959 radiotherapy Methods 0.000 claims description 5
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
206010009944 Colon cancer Diseases 0.000 claims description 4
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
208000033766 Prolymphocytic Leukemia Diseases 0.000 claims description 4
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
208000009956 adenocarcinoma Diseases 0.000 claims description 4
201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
238000001514 detection method Methods 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
201000005962 mycosis fungoides Diseases 0.000 claims description 4
201000008968 osteosarcoma Diseases 0.000 claims description 4
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 3
208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
206010018338 Glioma Diseases 0.000 claims description 3
208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
206010029260 Neuroblastoma Diseases 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
206010057644 Testis cancer Diseases 0.000 claims description 3
238000002591 computed tomography Methods 0.000 claims description 3
201000010536 head and neck cancer Diseases 0.000 claims description 3
208000014829 head and neck neoplasm Diseases 0.000 claims description 3
238000003384 imaging method Methods 0.000 claims description 3
238000002559 palpation Methods 0.000 claims description 3
238000002428 photodynamic therapy Methods 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
206010038038 rectal cancer Diseases 0.000 claims description 3
201000001275 rectum cancer Diseases 0.000 claims description 3
201000003120 testicular cancer Diseases 0.000 claims description 3
UJQBOUAGWGVOTI-XSSZXYGBSA-N 1-[(2r,4s,5r)-4-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@](O)(N=[N+]=[N-])C1 UJQBOUAGWGVOTI-XSSZXYGBSA-N 0.000 claims description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
201000003076 Angiosarcoma Diseases 0.000 claims description 2
206010003571 Astrocytoma Diseases 0.000 claims description 2
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
206010005003 Bladder cancer Diseases 0.000 claims description 2
208000003174 Brain Neoplasms Diseases 0.000 claims description 2
206010008342 Cervix carcinoma Diseases 0.000 claims description 2
208000005243 Chondrosarcoma Diseases 0.000 claims description 2
201000009047 Chordoma Diseases 0.000 claims description 2
208000006332 Choriocarcinoma Diseases 0.000 claims description 2
208000009798 Craniopharyngioma Diseases 0.000 claims description 2
201000009051 Embryonal Carcinoma Diseases 0.000 claims description 2
206010014967 Ependymoma Diseases 0.000 claims description 2
208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
201000008808 Fibrosarcoma Diseases 0.000 claims description 2
208000032612 Glial tumor Diseases 0.000 claims description 2
208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
208000017604 Hodgkin disease Diseases 0.000 claims description 2
208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims description 2
208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
208000007054 Medullary Carcinoma Diseases 0.000 claims description 2
208000000172 Medulloblastoma Diseases 0.000 claims description 2
206010027406 Mesothelioma Diseases 0.000 claims description 2
208000005927 Myosarcoma Diseases 0.000 claims description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
201000010133 Oligodendroglioma Diseases 0.000 claims description 2
208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 2
208000007641 Pinealoma Diseases 0.000 claims description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
201000000582 Retinoblastoma Diseases 0.000 claims description 2
201000010208 Seminoma Diseases 0.000 claims description 2
208000000453 Skin Neoplasms Diseases 0.000 claims description 2
208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 2
201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims description 2
206010043276 Teratoma Diseases 0.000 claims description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
208000008383 Wilms tumor Diseases 0.000 claims description 2
208000004064 acoustic neuroma Diseases 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
201000001531 bladder carcinoma Diseases 0.000 claims description 2
208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
201000010881 cervical cancer Diseases 0.000 claims description 2
208000002445 cystadenocarcinoma Diseases 0.000 claims description 2
239000003995 emulsifying agent Substances 0.000 claims description 2
208000037828 epithelial carcinoma Diseases 0.000 claims description 2
201000004101 esophageal cancer Diseases 0.000 claims description 2
206010017758 gastric cancer Diseases 0.000 claims description 2
201000002222 hemangioblastoma Diseases 0.000 claims description 2
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
206010024627 liposarcoma Diseases 0.000 claims description 2
201000005296 lung carcinoma Diseases 0.000 claims description 2
208000037829 lymphangioendotheliosarcoma Diseases 0.000 claims description 2
208000012804 lymphangiosarcoma Diseases 0.000 claims description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
201000001441 melanoma Diseases 0.000 claims description 2
206010027191 meningioma Diseases 0.000 claims description 2
201000002077 muscle cancer Diseases 0.000 claims description 2
201000002528 pancreatic cancer Diseases 0.000 claims description 2
208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
208000004019 papillary adenocarcinoma Diseases 0.000 claims description 2
201000010198 papillary carcinoma Diseases 0.000 claims description 2
208000024724 pineal body neoplasm Diseases 0.000 claims description 2
201000004123 pineal gland cancer Diseases 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 2
201000000849 skin cancer Diseases 0.000 claims description 2
208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
201000011549 stomach cancer Diseases 0.000 claims description 2
206010042863 synovial sarcoma Diseases 0.000 claims description 2
238000012285 ultrasound imaging Methods 0.000 claims description 2
208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
210000002700 urine Anatomy 0.000 claims description 2
239000000080 wetting agent Substances 0.000 claims description 2
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
239000002671 adjuvant Substances 0.000 claims 2
201000006966 adult T-cell leukemia Diseases 0.000 claims 2
238000011393 cytotoxic chemotherapy Methods 0.000 claims 2
239000002245 particle Substances 0.000 claims 2
208000031886 HIV Infections Diseases 0.000 claims 1
208000037357 HIV infectious disease Diseases 0.000 claims 1
210000000941 bile Anatomy 0.000 claims 1
201000010983 breast ductal carcinoma Diseases 0.000 claims 1
238000009104 chemotherapy regimen Methods 0.000 claims 1
239000002270 dispersing agent Substances 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
230000001613 neoplastic effect Effects 0.000 claims 1
230000002335 preservative effect Effects 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 75
229960002555 zidovudine Drugs 0.000 description 72
230000005764 inhibitory process Effects 0.000 description 62
102000055501 telomere Human genes 0.000 description 60
210000003411 telomere Anatomy 0.000 description 60
241001465754 Metazoa Species 0.000 description 54
150000001875 compounds Chemical class 0.000 description 54
229930012538 Paclitaxel Natural products 0.000 description 47
229960001592 paclitaxel Drugs 0.000 description 47
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 47
230000000259 anti-tumor effect Effects 0.000 description 39
239000003814 drug Substances 0.000 description 32
229940079593 drug Drugs 0.000 description 28
239000002246 antineoplastic agent Substances 0.000 description 21
210000003932 urinary bladder Anatomy 0.000 description 19
241000699670 Mus sp. Species 0.000 description 17
239000008194 pharmaceutical composition Substances 0.000 description 15
230000035755 proliferation Effects 0.000 description 15
102000018233 Fibroblast Growth Factor Human genes 0.000 description 14
108050007372 Fibroblast Growth Factor Proteins 0.000 description 14
230000008901 benefit Effects 0.000 description 13
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
229940127089 cytotoxic agent Drugs 0.000 description 12
230000001988 toxicity Effects 0.000 description 12
231100000419 toxicity Toxicity 0.000 description 12
241000282472 Canis lupus familiaris Species 0.000 description 11
-1 PPS Chemical compound 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
230000007774 longterm Effects 0.000 description 11
210000002307 prostate Anatomy 0.000 description 11
230000004083 survival effect Effects 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000030833 cell death Effects 0.000 description 10
229960002949 fluorouracil Drugs 0.000 description 10
238000004904 shortening Methods 0.000 description 10
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 10
230000001093 anti-cancer Effects 0.000 description 9
230000006907 apoptotic process Effects 0.000 description 9
238000003556 assay Methods 0.000 description 9
239000002254 cytotoxic agent Substances 0.000 description 9
231100000599 cytotoxic agent Toxicity 0.000 description 9
230000007423 decrease Effects 0.000 description 9
239000002609 medium Substances 0.000 description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 8
230000027455 binding Effects 0.000 description 8
210000000481 breast Anatomy 0.000 description 8
229960004562 carboplatin Drugs 0.000 description 8
230000010261 cell growth Effects 0.000 description 8
230000003034 chemosensitisation Effects 0.000 description 8
230000003013 cytotoxicity Effects 0.000 description 8
231100000135 cytotoxicity Toxicity 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
230000036210 malignancy Effects 0.000 description 8
231100000252 nontoxic Toxicity 0.000 description 8
230000003000 nontoxic effect Effects 0.000 description 8
210000003800 pharynx Anatomy 0.000 description 8
230000009758 senescence Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
230000009885 systemic effect Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
230000004614 tumor growth Effects 0.000 description 8
108010072866 Prostate-Specific Antigen Proteins 0.000 description 7
102100038358 Prostate-specific antigen Human genes 0.000 description 7
210000004748 cultured cell Anatomy 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
238000001802 infusion Methods 0.000 description 7
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000004044 response Effects 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
241000282412 Homo Species 0.000 description 6
230000008030 elimination Effects 0.000 description 6
238000003379 elimination reaction Methods 0.000 description 6
238000002513 implantation Methods 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
231100000518 lethal Toxicity 0.000 description 6
230000001665 lethal effect Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
238000005549 size reduction Methods 0.000 description 6
238000011269 treatment regimen Methods 0.000 description 6
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
108700020796 Oncogene Proteins 0.000 description 5
108091093037 Peptide nucleic acid Proteins 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000002113 chemopreventative effect Effects 0.000 description 5
230000000973 chemotherapeutic effect Effects 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 5
235000008191 folinic acid Nutrition 0.000 description 5
239000011672 folinic acid Substances 0.000 description 5
229960001691 leucovorin Drugs 0.000 description 5
238000011866 long-term treatment Methods 0.000 description 5
230000003211 malignant effect Effects 0.000 description 5
206010061289 metastatic neoplasm Diseases 0.000 description 5
231100000956 nontoxicity Toxicity 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
230000005855 radiation Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
102100034343 Integrase Human genes 0.000 description 4
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
238000011394 anticancer treatment Methods 0.000 description 4
230000010100 anticoagulation Effects 0.000 description 4
230000001640 apoptogenic effect Effects 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
239000006114 chemosensitizer Substances 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
229960004679 doxorubicin Drugs 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000002349 favourable effect Effects 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000036541 health Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000001394 metastastic effect Effects 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
238000007910 systemic administration Methods 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
102000036365 BRCA1 Human genes 0.000 description 3
206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010036774 Proctitis Diseases 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000025084 cell cycle arrest Effects 0.000 description 3
230000032823 cell division Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
231100000371 dose-limiting toxicity Toxicity 0.000 description 3
230000000857 drug effect Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
231100000324 minimal toxicity Toxicity 0.000 description 3
239000002105 nanoparticle Substances 0.000 description 3
230000017095 negative regulation of cell growth Effects 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000010076 replication Effects 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
102000003390 tumor necrosis factor Human genes 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
238000005303 weighing Methods 0.000 description 3
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
108700040618 BRCA1 Genes Proteins 0.000 description 2
101150072950 BRCA1 gene Proteins 0.000 description 2
108700010154 BRCA2 Genes Proteins 0.000 description 2
101150008921 Brca2 gene Proteins 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
102000052510 DNA-Binding Proteins Human genes 0.000 description 2
101710116602 DNA-Binding protein G5P Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102100020873 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000003923 Protein Kinase C Human genes 0.000 description 2
108090000315 Protein Kinase C Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010038111 Recurrent cancer Diseases 0.000 description 2
101710162453 Replication factor A Proteins 0.000 description 2
101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 2
101710176276 SSB protein Proteins 0.000 description 2
101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 2
108010011834 Streptolysins Proteins 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
101710183280 Topoisomerase Proteins 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000003098 androgen Substances 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000002429 anti-coagulating effect Effects 0.000 description 2
229940034982 antineoplastic agent Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000012829 chemotherapy agent Substances 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
230000034994 death Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229960001904 epirubicin Drugs 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
230000004907 flux Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
201000009277 hairy cell leukemia Diseases 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000003463 hyperproliferative effect Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000005917 in vivo anti-tumor Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
231100000225 lethality Toxicity 0.000 description 2
239000006210 lotion Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000008450 motivation Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
239000002547 new drug Substances 0.000 description 2
238000012148 non-surgical treatment Methods 0.000 description 2
230000004987 nonapoptotic effect Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
201000001514 prostate carcinoma Diseases 0.000 description 2
208000023958 prostate neoplasm Diseases 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000008943 replicative senescence Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
229940063683 taxotere Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
229920001221 xylan Polymers 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
229940121819 ATPase inhibitor Drugs 0.000 description 1
208000037068 Abnormal Karyotype Diseases 0.000 description 1
206010001367 Adrenal insufficiency Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
108700020463 BRCA1 Proteins 0.000 description 1
102000052609 BRCA2 Human genes 0.000 description 1
108700020462 BRCA2 Proteins 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
101100494265 Caenorhabditis elegans best-15 gene Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108090000323 DNA Topoisomerases Proteins 0.000 description 1
102000003915 DNA Topoisomerases Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
108050009160 DNA polymerase 1 Proteins 0.000 description 1
229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000160765 Erebia ligea Species 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229920001499 Heparinoid Polymers 0.000 description 1
102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 1
101000998810 Homo sapiens Insulin-like peptide INSL6 Proteins 0.000 description 1
206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102100033235 Insulin-like peptide INSL6 Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000243985 Onchocerca volvulus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
241000127464 Paubrasilia echinata Species 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
208000007660 Residual Neoplasm Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
241000223892 Tetrahymena Species 0.000 description 1
241000906446 Theraps Species 0.000 description 1
239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
208000017515 adrenocortical insufficiency Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940044684 anti-microtubule agent Drugs 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
238000011717 athymic nude mouse Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical group O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
201000007180 bile duct carcinoma Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000005068 bladder tissue Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
229960002727 cefotaxime sodium Drugs 0.000 description 1
AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000003711 chorioallantoic membrane Anatomy 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000000448 cultured tumor cell Anatomy 0.000 description 1
230000001955 cumulated effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
231100000409 cytocidal Toxicity 0.000 description 1
230000000445 cytocidal effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
230000007608 epigenetic mechanism Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960004750 estramustine phosphate Drugs 0.000 description 1
ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002509 fluorescent in situ hybridization Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
230000000762 glandular Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
239000002554 heparinoid Substances 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
208000029824 high grade glioma Diseases 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000010249 in-situ analysis Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
238000001325 log-rank test Methods 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
201000011614 malignant glioma Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000000051 modifying effect Effects 0.000 description 1
239000012778 molding material Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
FVSUYFWWFUVGRG-UHFFFAOYSA-N naphthalen-1-ylurea Polymers C1=CC=C2C(NC(=O)N)=CC=CC2=C1 FVSUYFWWFUVGRG-UHFFFAOYSA-N 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
230000027405 negative regulation of phosphorylation Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
231100001083 no cytotoxicity Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
208000002042 onchocerciasis Diseases 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
229940127084 other anti-cancer agent Drugs 0.000 description 1
229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
239000002304 perfume Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000003881 protein kinase C inhibitor Substances 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
208000024725 retina neoplasm Diseases 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
108010057210 telomerase RNA Proteins 0.000 description 1
230000033863 telomere maintenance Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000012447 xenograft mouse model Methods 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Dermatology (AREA)
Virology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2004209428A 2003-01-31 2004-01-30 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors Abandoned AU2004209428A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US44406103P	2003-01-31	2003-01-31
US60/444,061		2003-01-31
PCT/US2004/002609 WO2004070008A2 (fr)	2003-01-31	2004-01-30	Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase

Publications (1)

Publication Number	Publication Date
AU2004209428A1 true AU2004209428A1 (en)	2004-08-19

Family

ID=32850822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004209428A Abandoned AU2004209428A1 (en)	2003-01-31	2004-01-30	Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors

Country Status (6)

Country	Link
EP (1)	EP1606302A4 (fr)
JP (1)	JP2007525414A (fr)
CN (1)	CN1768075A (fr)
AU (1)	AU2004209428A1 (fr)
CA (1)	CA2515000A1 (fr)
WO (1)	WO2004070008A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS59363B1 (sr) *	2012-12-07	2019-11-29	Geron Corp	Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
BR112019012045A2 (pt)	2016-12-13	2020-08-18	Beta Therapeutics Pty Ltd	inibidores de heparanase e uso dos mesmos
WO2018107226A1 (fr) *	2016-12-13	2018-06-21	Beta Therapeutics Pty. Ltd.	Méthodes de traitement de troubles oculaires
US11787783B2 (en)	2016-12-13	2023-10-17	Beta Therapeutics Pty Ltd	Heparanase inhibitors and use thereof
JPWO2022114111A1 (fr) *	2020-11-27	2022-06-02
CN119770468B (zh) *	2025-01-03	2025-10-31	中国人民解放军军事科学院军事医学研究院	苏拉明钠在预防和/或治疗放射性肠损伤中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5882893A (en) *	1997-12-04	1999-03-16	Millennium Pharmaceuticals, Inc.	Nucleic acids encoding muscarinic receptors and uses therefor

2004
- 2004-01-30 AU AU2004209428A patent/AU2004209428A1/en not_active Abandoned
- 2004-01-30 CN CNA2004800091217A patent/CN1768075A/zh active Pending
- 2004-01-30 WO PCT/US2004/002609 patent/WO2004070008A2/fr not_active Ceased
- 2004-01-30 CA CA002515000A patent/CA2515000A1/fr not_active Abandoned
- 2004-01-30 JP JP2006503176A patent/JP2007525414A/ja active Pending
- 2004-01-30 EP EP04706977A patent/EP1606302A4/fr not_active Withdrawn

Also Published As

Publication number	Publication date
JP2007525414A (ja)	2007-09-06
WO2004070008A3 (fr)	2005-05-26
EP1606302A4 (fr)	2009-02-18
WO2004070008A2 (fr)	2004-08-19
CN1768075A (zh)	2006-05-03
CA2515000A1 (fr)	2004-08-19
EP1606302A2 (fr)	2005-12-21
WO2004070008A8 (fr)	2005-09-29

Publication	Publication Date	Title
US20050282893A1 (en)	2005-12-22	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
KR102615210B1 (ko)	2023-12-18	난소암의 치료에 사용되는 티노스타무스틴
AU2014229985B2 (en)	2018-12-13	Methods of treating colorectal cancer
WO2013157010A1 (fr)	2013-10-24	Méthodes et compositions pour le traitement du cancer à base d'arni
EP4233879B1 (fr)	2025-07-23	Dérivés de désoxycytidine destinés à être utilisés dans des thérapies anticancéreuses
US20160090636A1 (en)	2016-03-31	MicroRNA-129 AS A BIOMARKER FOR COLORECTAL CANCER
AU2004209428A1 (en)	2004-08-19	Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
WO2017162185A1 (fr)	2017-09-28	Aptamère d'acide ribonucléique présentant un effet inhibiteur sur le cancer du poumon à non petites cellules, et composition pharmaceutique le comprenant
RU2651493C2 (ru)	2018-04-19	NOTCH 1-СПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ миРНК
KR20210144754A (ko)	2021-11-30	암을 치료하기 위한 방법 및 조성물
CN112996568A (zh)	2021-06-18	用于调节mir-10b活性的微小rna化合物和方法
CN106714795A (zh)	2017-05-24	用于治疗尤因家族肿瘤的组合物及方法
US20080318891A1 (en)	2008-12-25	Antisense oligonucleotides against thymidylate synthase
EP3955943A1 (fr)	2022-02-23	Polythérapie avec du gmci et du ddri pour le traitement du cancer
JPWO2009069668A1 (ja)	2011-04-14	悪性黒色腫抗原の発現上昇剤及びその用途
US11771777B2 (en)	2023-10-03	Three-dimensional self-assembled nucleic acid nanoparticles and use thereof
AU2022384267A1 (en)	2024-05-23	Lncrna transcripts in melanomagenesis
AU2022474010A1 (en)	2025-02-20	Compositions for and methods of precision cancer treatment
JP2008502588A (ja)	2008-01-31	ラミニン−５調節物質及びその使用
EP3515443B1 (fr)	2022-06-22	Composition combinée pour la prévention ou le traitement du cancer comprenant un dérivé de benzophénone thiazole en tant que vda et un inhibiteur de topo-isomérase
Nakanishi et al.	1999	Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil
AU2023393488A1 (en)	2025-07-24	Compositions for inihibition of kras expression and methods of use thereof
HK40091434A (en)	2023-12-08	Deoxy- cytidine derivatives for use in cancer therapies
KR20230059641A (ko)	2023-05-03	대장암의 치료 및 전이 억제용 조성물 및 이의 용도
US20210246127A1 (en)	2021-08-12	Compounds and methods targeting gper for treatment of diseases associated with calcium

Legal Events

Date	Code	Title	Description
2011-08-25	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application